

Alzheimer's Disease Research: Genetics, Targets & Drugs

A Scientific Conference, Hosted by Amgen

Thursday, November 2, 2017

Post-Doc Visit 10:30 a.m. Conference 12:00 p.m. – 5:00 p.m.

Networking Reception to Follow

Amgen Massachusetts

Time	Activity/Topic	Details/Speaker
10:30 a.m.	Post-Doc Arrival & Registration	Zaven Kaprielian, Director, Research, Amgen
10:45 a.m.	Post-Doc Tours Escorts: Paul Andrews, Violeta Yu, Jacinthe Gingras, Manuela Polydoro, Mark Zervas	Second Floor: Hologram (Kristin Andrews, Alan Sickmeir) 7 th Floor: Automated e-phys screening platform (Dan Gillie, Dave Matson) NGL labs (Heather Nunn)
11:30 a.m.	Post-Doc Lunch	
12:00 p.m.	Conference Registration Opens	
12:30 p.m.	Welcome	Zaven Kaprielian, Director, Research, Amgen Steve Wood, Scientific Director, Amgen
	Human Genetics and Alzheimer's Disease Target Identification	John Dunlop Vice President, Discovery Research, Amgen
1:00 p.m.	Targeting β Amyloid to Prevent Alzheimer's Disease: Pre-clinical Efforts at Amgen	Steve Wood Scientific Director, Amgen
1:30 p.m.	TREM2: From Genetics to Drug Discovery	Shilpa Sambashivan Senior Scientist, Amgen
2:00 p.m.	Coffee Break/Networking	
2:15 p.m.	Targeting β Amyloid to Prevent Alzheimer's Disease: Phase 3 Clinical Program	Vissia Viglietta, Executive Medical Director of Global Development, Amgen
2:45 p.m.	Chemical Neurobiology of Tauopathy: Models to Molecules	Stephen Haggarty Associate Professor of Neurology, Director, Chemical Neurobiology Lab, Massachusetts General Hospital, Harvard Medical School
3:15 p.m.	Saving the Synapse in Alzheimer's Disease: Lessons from Development	Beth Stevens Associate Professor, FM Kirby Neurobiology Research Center, Boston Children's Hospital, Harvard Medical School
3:45 p.m.	Coffee Break/Networking	

Time	Activity/Topic	Details/Speaker
-------------	-----------------------	------------------------

4:00 p.m.	Panel Discussion	Moderator: John Dunlop Panelists: Vissia Viglietta, Stephen Haggarty, Beth Stevens, Barbara Tate (SV Life Sciences), Ricardo Dolmetsch (Novartis), Chris Henderson (Biogen)
5:00 p.m.	Closing Remarks	John Dunlop, Vice President, Discovery Research, Amgen
	Networking Reception until 7:00 p.m.	